Guerbet Stock (GBT.PA): Analysis & Outlook

Guerbet Stock Price: Live Quote

Guerbet stock trades on Euronext Paris under the ticker GBT. The share price currently stands at €6,84 €, with a move of -0,44% over the session. Over the past twelve months, the stock has traded between €5,80 € and €18,26 €, with daily volumes of around 2 506 shares — the ordinary liquidity of a healthcare mid-cap listed in Paris. A French company listed in euros, Guerbet is eligible for the PEA — France’s tax-advantaged share savings plan (Plan d’Épargne en Actions).

Guerbet at a Glance: The Global Contrast Media Specialist

Guerbet is a century-old French family company that has become the global specialist in contrast media — the drugs injected before a medical scan to reveal vessels, organs or lesions.

Born in the interwar years from its founder’s discovery of iodinated products, the House has built a unique position: one of the very few laboratories in the world dedicated outright to this therapeutic class, present across all three major families — iodinated products for CT, chelated agents for MRI, and the innovations that extend both platforms.

Ouvrir un compte Vantage →

Its customers are the hospitals and imaging centers of the whole world: statistically, every CT or MRI injection is a dose sold by Guerbet or by one of its two large global rivals — a three-player oligopoly market, structurally rational.

The resulting profile for the investor: a healthcare company defensive in its demand — medical imaging grows with aging populations and earlier diagnosis — yet cyclical in its industrial episodes: the historic production plant, hospital price regulation and the competitors’ comebacks have marked the recent years, turning the quiet family company into an industrial turnaround story watched closely by the market.

Why the Guerbet Share Price Moves

Three families of signals govern the stock. The half-yearly publications first: sales growth by region and by platform, operating margin — the central indicator of the turnaround — and debt, the acquisition of a competitor’s imaging division having left on the balance sheet a debt the group is reducing through discipline and divestments.

Then the market fundamentals: global imaging procedure volumes — CT and MRI are progressing structurally — hospitals’ trade-offs between generics and brands, and the three-player competition that frames prices. And finally the industrial and regulatory events: inspections of production sites, health-authority approvals of the new formulations — including the environmentally oriented products reducing the impact of contrast-agent discharges — and possible litigation, every incident in this industry being paid for in confidence.

On this case, the reading of the half-years comes first: the margin-debt trajectory tells the turnaround, the rest accompanies it.

The Contrast Media Market: A Global Oligopolistic Niche

Understanding Guerbet means understanding the structure of its market. Contrast media combine three barriers to entry: complex chemistry — synthesizing the iodinated and chelated molecules takes rare industrial know-how — dedicated plants subject to the strictest pharmaceutical controls, and regulatory qualifications that take years to secure market by market.

The result: three players dominate the planet — Guerbet and two larger groups for which imaging is only a division — in a competitive balance that protects prices better than in plain generics. Demand, for its part, benefits from two structural tailwinds: demographic aging — more imaging per capita — and the expansion of equipment in the emerging countries, where every newly installed scanner creates recurring demand for doses.

In the long run, the central question of the case: the share innovation will capture — lower-dose products, traceability, environmental profile — in a market that is generic by nature.

The Stock’s History and Market Performance

Guerbet’s stock market trajectory reads in two eras. The long family stability: the House, controlled by the founding family across the generations, offered the profile of a quiet income stock — regular dividend, defensive activity, modest capitalization.

Then the transforming episode: the acquisition of a global laboratory’s imaging division, a sizeable operation for a company of this capitalization, which doubled the group’s scale while leaving a significant debt on the balance sheet — followed by the years of consolidation: divestment of non-strategic assets, industrial efficiency plans, a pandemic that disrupted procedure volumes — non-urgent imaging having been suspended — then recovery.

The stock has lived since in the logic of the turnaround: every half-year of improved margin and reduced debt revalues the thesis, every setback punishes it — the family company having mutated into a special-situation stock, followed as such by investors.

The Guerbet Dividend: Suspended While Debt Comes Down

Distributions were suspended during the high-debt phase — the priority of creditors and of the financial plan over shareholder remuneration, the classic choice of turnarounds. The dividend currently stands at €— per share — its restoration, when it comes, will mark the culmination of the thesis: the company recovering its family calling of income stock, the distribution once again the signal of a cleaned-up balance sheet.

Income investors will watch this exit point; special-situation investors will read in it the terminal catalyst of the re-rating. In a PEA, where applicable, the wrapper’s tax treatment would accompany that return — the case’s horizon, a full deleveraging cycle, naturally coinciding with the five years of the exemption.

Who Owns Guerbet? The Family at the Helm

The capital keeps its historic family shape: the founding line, through its holdings, remains the reference shareholder — House governance in which decisions are taken in the continuity of the generations, management working hand in hand with the family on the long-term strategy. This structure shaped the case: the transforming acquisition itself, risky for a modest capitalization, was wanted and carried by the family — the sign of a patrimonial ambition that outlives the funds’ horizon.

For the minority shareholder, this setup brings stability — no activism, no break-up — and demands trust: the thesis is judged against the family plan, each of its steps — divestments, dividend restoration — unfolding over time. Institutions complete the register, the free float remaining liquid on Euronext for everyday trading.

Competitors and Landscape: The Three-Player Oligopoly

The competitive landscape comes down to two names: Bracco, the Italian family house leading the market — Guerbet’s counterpart across the Alps, at a larger scale — and GE HealthCare, whose diagnostic pharmaceuticals division includes the contrast agents — the American giant’s presence balancing the oligopoly.

Against these two players, Guerbet plays the pure-specialist card: the only listed company in the world whose entire business is contrast media — an argument for investors screening medical imaging stocks for pure exposure to this niche, where the competitors offer only a fraction of their activities. Competition plays out on hospital tenders, industrial quality and innovation — every point of share won or lost is contested dose by dose, market by market.

Guerbet Financial Data

The indicators below frame the fundamental reading of the case; the detailed figures are compiled by our data team and updated after every publication.

Is Guerbet a Good Investment in 2026?

The strengths of the case: a global oligopolistic position in a niche guarded by barriers — chemistry, plants, regulation; structural demand — demographics and preventive imaging; the status of the sector’s only listed pure play; family governance committed over the long run; and PEA eligibility — a singular build among French pharma stocks.

The risks: the execution of the turnaround — margin and debt have not yet had the last word; the dependence on hospital prices, which health systems compress; the industrial weight of a historic site whose incidents are paid for in credibility; and the competition of two larger players whose means exceed those of the French House.

The right allocation is that of special situations: a position built in tranches on the troughs of confidence, whose central scenario — deleveraging completed, dividend restored, multiple normalized — validates in stages, each half-year bringing its building block or its wake-up call.

How to Buy Guerbet Shares from France

A French stock listed on Euronext Paris, Guerbet is bought in a PEA or in an ordinary securities account through a broker covering the Paris exchange — our comparison of online brokers sets out the real fees. As the stock trades in euros, no currency-conversion fees apply.

On a special-situation stock whose half-years move the share, the limit order placed around the publications protects against gaps, and building the position in tranches during the phases of doubt about the turnaround — rather than at the summits of confidence — is the fitting discipline. For multi-asset trading beyond shares, specialized platforms remain accessible by opening a Vantage account →. Finally, the guide how to buy shares covers every step of the journey.

Contrast Agents and the Environment: The Regulatory Turn

A quiet industry undertaking is redrawing the niche: the environmental impact of contrast media. Injected agents end up partly in the wastewater of hospitals — a measurable trace that has put the subject on the European regulators’ agenda, between reprocessing standards, incentives for leaner formulations and the monitoring of aquatic environments.

For manufacturers, this turn translates into concrete programs: reduced-dose formulations, chemistry that is easier to eliminate, recovery devices — all patentable innovations able to renew the three-player oligopoly in favor of whoever secures the regulatory lead. For Guerbet, the stakes are strategic on two counts: compliance — anticipating the standards protects the positions — and differentiation — embodying « sustainable » contrast offers an argument with hospitals themselves assessed on their discharges.

The group’s publications report on these programs: the ESG-product line deserves the same reading as the sales — it is the card of the next round of the competition.

How to Follow the Guerbet Story Through the Year

Three appointments pace the year. The half-yearly results: the margin-debt pair — the two lines of the turnaround — is read there as a trend, management guiding for the year; it is the moment that moves the stock. The regulatory announcements: approvals of the new formulations, inspections of the sites — every industrial event weighing on the plan’s credibility. And the life of the sector: competitors’ releases, major hospital tenders, scientific publications on imaging.

The reading rule of a special situation: judge the trajectory, not the level — a disappointing half-year on a sound slope is forgiven, a good half-year on a broken slope is not celebrated.

Frequently Asked Questions About Guerbet Stock

What Exactly Does Guerbet Make?

Contrast media — the drugs injected before a CT scan or an MRI to visualize vessels, organs and lesions: iodinated molecules for CT, chelated agents for MRI, and the associated innovations. Medical imaging worldwide consumes its doses at every examination.

Is Guerbet Still a Family Company?

Yes: the founding family, present since the origins for nearly a century, remains the reference shareholder through its holdings — House governance steering the long-term strategy, the transforming acquisition having been wanted and carried by this family structure.

Why Has the Stock Changed Profile So Much?

The acquisition of a major laboratory’s imaging division doubled the group’s scale while significantly indebting it: the family income stock became a turnaround case — margin to restore, debt to reduce, dividend suspended then called to be reborn, every half-year weighing on the thesis.

Can You Buy Guerbet in a PEA?

Yes: a French company listed on Euronext Paris, the stock is PEA-eligible — the horizon of full deleveraging matching the five years of the wrapper.

Is the Dividend Restoration Close?

It is the terminal catalyst of the thesis — it cannot be decreed any more than it can be predicted: the debt-margin trajectory decides, and management will confirm it once the plan is complete. Investors follow the « dividend » line of every half-year as the thermometer of the turnaround.

What Is the Main Risk of the Stock?

What Is the Main Risk of the Stock?

The industrial-financial pair: an incident at the historic production site or a margin setback calls the turnaround’s calendar into question — on a special-situation stock, the credibility of the trajectory is worth more than the absolute level of the figures.

Where Are Guerbet Doses Produced?

At the group’s industrial sites — including the historic French plant — completed by the network inherited from the transforming acquisition: a pharmaceutical production map subject to the controls of each zone’s health authorities. Its robustness is part of the case: every qualified site is one more competitive barrier.

Imaging Demand: The Deep Tailwinds

Behind the quarterly ups and downs, the consumption of contrast media follows long-term trends that investors do well to know. Demographic aging first: diagnostic imaging grows with the age of populations — more examinations per capita in aging societies, Europe and East Asia at the fore.

Screening and early diagnosis next: health policies keep recommending more imaging — broader screenings, the monitoring of chronic conditions — every added protocol converting recommendations into procedures, then into doses. And finally the equipment of the emerging countries: every CT scanner and every MRI installed in a developing country creates recurring demand for contrast media — an installed base extending faster than the population, for decades.

These three currents do not make the half-years — hospital prices and short-term volumes make those — but they make the decade: the bedrock of the case, for whoever looks beyond the next report.

Key Takeaways

• Listing: Euronext Paris, ticker GBT, in euros — PEA-eligible.
• Profile: the global contrast-media specialist — a three-player oligopoly, a century-old family House.
• Price drivers: the margin-debt trajectory of the turnaround, global imaging volumes, the dividend restoration.
• Dividend: suspended — its rebirth is the final catalyst of the thesis.
• Key risk: industrial execution + debt — a special-situation position, built in tranches on the troughs.